Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
Launched by MASSACHUSETTS GENERAL HOSPITAL · Mar 28, 2025
Trial Information
Current as of July 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new artificial intelligence (AI) tool that analyzes chest X-ray images to help doctors identify patients who are at a higher risk of developing lung cancer. The main goal is to see if this AI tool can encourage more patients to participate in lung cancer screening with a special CT scan, which can help catch the disease early. Researchers will compare two groups of patients: one group that receives alerts from the AI tool and another group that does not, to find out if the alerts lead to more people getting screened within six months after their doctor visit.
To be eligible for this trial, participants must be between 50 and 77 years old, have a history of smoking, and have had a chest X-ray in the past two years. They should also have a scheduled outpatient appointment with a participating doctor. However, individuals with signs of lung cancer or who have had certain recent chest scans will not be able to participate. If you join this study, you will help researchers learn more about how technology can improve lung cancer screening and potentially save lives.
Gender
ALL
Eligibility criteria
- Major Inclusion Criteria:
- • Scheduled outpatient appointment with participating provider.
- • 50- to 77-year-old who currently or formerly smoked, to include persons potentially eligible for lung screening based on Medicare guidelines.
- • Recent (within 2 years) PA chest radiograph.
- Exclusion Criteria:
- • • History or signs/symptoms of lung cancer. Recent (within 2 years) chest CT. Clinical indication for chest CT beyond lung cancer screening.
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported